Peter Rahmer - 30 May 2023 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Title: Chief Corporate Development Officer
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
30 May 2023
Net transactions value
$0
Form type
4
Filing time
01 Jun 2023, 18:24:27 UTC
Previous filing
01 Jun 2023
Next filing
28 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Award $0 +161,818 +103% $0.000000 318,404 30 May 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
F2 Includes 291,332 shares underlying RSUs.

Remarks:

Title: Chief Corporate Development Officer